PCSK9 and familial hypercholesterolemia: In early 2000, proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein associated with the turn-over of the low-density lipoprotein receptors, was identified as a promising target for hypercholesterolemia treatment (6).